Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tucidinostat - HUYA Bioscience International

Drug Profile

Tucidinostat - HUYA Bioscience International

Alternative Names: Chidamide; CS-055; Epidaza; HBI-8000

Latest Information Update: 28 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chipscreen Biosciences
  • Developer Chipscreen Biosciences; GNT Biotech and Medicals Corporation; Guangxi Center for Disease Control and Prevention; HUYA Bioscience International; IQVIA; Zhejiang University
  • Class Aminopyridines; Antineoplastics; Benzamides; Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; HDAC1 protein inhibitors; HDAC10 protein inhibitors; HDAC2 protein inhibitors; HDAC3 protein inhibitors; Mitogen-activated protein kinase inhibitors; Proto oncogene protein c-akt inhibitors; Ras protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Peripheral T-cell lymphoma; Cutaneous T-cell lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Peripheral T-cell lymphoma
  • Phase III Breast cancer
  • Phase II/III Cutaneous T-cell lymphoma; HIV infections
  • Phase II Adult T-cell leukaemia-lymphoma; Non-small cell lung cancer
  • Phase I/II Solid tumours
  • No development reported Non-Hodgkin's lymphoma

Most Recent Events

  • 28 Oct 2019 No recent reports of development identified for phase-I development in Peripheral-T-cell-lymphoma(Combination therapy, Newly diagnosed) in China (PO, Tablet)
  • 04 Jun 2019 Chipscreen Biosciences plans a phase I trial for Non-Hodgkin's Lymphoma (Second line therapy or greater, Combination therapy) in China, in July 2019 (NCT03974243)
  • 17 Feb 2019 Chipscreen Biosciences and Innovent Biologics agree to evaluate combination of tucidinostat, sintilimab and IBI 305 for Colorectal cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top